Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

743 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multidrug-resistant urethritis caused by Haemophilus parainfluenzae: susceptibility pattern and fosfomycin as an alternative treatment.
Fidalgo BI, Iglesies J, García D, Vergara A, Fuertes de Vega I, Horvath L, Zboromyrska Y, Bosch J, González A, Riera-Monroig J, Roca I, Alguacil M, Casals-Pascual C, Pitart C, Mallolas J, Blanco JL, Espasa M. Fidalgo BI, et al. Among authors: horvath l. Sex Transm Infect. 2025 Jan 7:sextrans-2024-056142. doi: 10.1136/sextrans-2024-056142. Online ahead of print. Sex Transm Infect. 2025. PMID: 39773988 Free article. No abstract available.
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Conduit C, Inderjeeth AJ, Allen R, Martin AJ, Parulekar W, Mulroe E, McJannett M, Zielinski RR, Thomson A, Tan TH, Sandhu SK, Reaume MN, Pook DW, North SA, Marx GM, Joshua A, Horvath L, McDermott R, Chowdhury S, Chi KN, Zhang AY, Stockler MR, Davis ID, Sweeney CJ; ANZUP Cancer Trials Group. Conduit C, et al. Among authors: horvath l. Future Oncol. 2025 Jan 17:1-10. doi: 10.1080/14796694.2024.2440277. Online ahead of print. Future Oncol. 2025. PMID: 39819293 Free article.
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy.
Mellor R, Ardolino L, Scheinberg T, Fitzpatrick M, Lin HM, Bonnitcha P, Sullivan D, Meikle PJ, Stockler MR, Moujaber T, Joshua A, Horvath L. Mellor R, et al. Among authors: horvath l. Ther Adv Med Oncol. 2024 Dec 16;16:17588359241307814. doi: 10.1177/17588359241307814. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39691585 Free PMC article.
Prognostic impact of targetable driver alterations in resected early-stage lung cancer.
Terbuch A, Konjic S, Schlintl V, Absenger G, Jost PJ, Lindenmann J, Swatek P, John N, John T, Wurm R, Zacharias M, Posch F, Hochmair MJ, Fabikan H, Weinlinger C, Illini O, Horvath L, Gamerith G, Wolf D, Augustin F, Brcic L. Terbuch A, et al. Among authors: horvath l. Transl Lung Cancer Res. 2024 Nov 30;13(11):3096-3105. doi: 10.21037/tlcr-24-433. Epub 2024 Nov 14. Transl Lung Cancer Res. 2024. PMID: 39670019 Free PMC article.
743 results